


**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

Claims 1-16 (canceled)

Claim 17 (previously presented): A method of treating Bcr/Abl-positive leukemia resistant to a compound of formula I



(I)

comprising administering to a patient in need thereof a combination of (a) a cyclin-dependent kinase inhibitor and (b) 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino]phenyl]-benzamide in which the active ingredients (a) and (b) are present in each case in free form or in the form of a pharmaceutically acceptable salt, and optionally at least one pharmaceutically acceptable carrier, for simultaneous, separate or sequential use.

Claim 18 (previously presented): The method according to claim 1 wherein the Bcr/Abl-positive leukemia resistant to compound of formula I over-expresses Bcr/Abl.

Claim 19 (previously presented): The method according to claim 17 wherein the cyclin-dependent kinase inhibitor is flavopiridol or E 7070 or CYC 202.

Claim 20 (previously presented): The method according to claim 17 wherein the cyclin-dependent kinase inhibitor is flavopiridol.

Claim 21 (currently amended): The method according to claim 20 wherein flavopiridol and 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino]phenyl]-benzamide are present in a synergistically effective molar ratio (FP/COMPOUND I) range of 1:1 to 1:10.

Claim 22 (previously presented): The method according to claim 17, wherein the active ingredients (a) and (b) are present in a synergistically effective amount.